Drug intelligence / Profile preview

AADvac2

Development stage: Preclinical
Lead developer: Axon Neuroscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AADvac2 is a fully humanized monoclonal antibody developed by AXON Neuroscience SE as a passive immunotherapy for the treatment of Alzheimer's disease and other tauopathies. It acts as a tau modulator by specifically targeting disease-modified tau protein, which is the primary component of neurofibrillary tangles associated with cognitive decline and brain atrophy. By binding to and neutralizing these pathological tau species, AADvac2 aims to prevent the spread of tau pathology and provide a disease-modifying effect. It is one of AXON Neuroscience's lead compounds, developed alongside their active tau vaccine, AADvac1.

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on AADvac2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AADvac2.

Explore the full profile